Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia (Q36428418)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia (English)

1 reference

Europe PubMed Central

14 August 2017

methicillin-resistant Staphylococcus aureus

0 references

0 references

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

Marc H. Scheetz

object named as

Marc H Scheetz

1

0 references

Richard G. Wunderink

object named as

Richard G Wunderink

2

0 references

4

object named as

Gary A Noskin

1 reference

Europe PubMed Central

14 August 2017

Michael J Postelnick

3

object named as

Michael J Postelnick

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

1 April 2006

1 reference

Europe PubMed Central

14 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

14 August 2017

26

1 reference

Europe PubMed Central

14 August 2017

4

1 reference

Europe PubMed Central

14 August 2017

539-550

1 reference

Europe PubMed Central

14 August 2017

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Real-time monitoring of intracellular Staphylococcus aureus replication

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Pulmonary disposition of vancomycin in critically ill patients.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Nosocomial pneumonia: therapy is just not good enough

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Pharmacokinetics of vancomycin in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Outcome assessment of minimizing vancomycin monitoring and dosing adjustments

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

The site concentrations of antimicrobial agents in the lung

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Protein permeability in the adult respiratory distress syndrome. Loss of size selectivity of the alveolar epithelium

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Comparative pharmacokinetics of the carbapenems: clinical implications

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Penetration of vancomycin into human lung tissue

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Vancomycin entry into lung lymph in sheep

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Validity of markers of dilution in small volume lung lavage.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Intrapulmonary pharmacokinetics of linezolid

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Protein binding and serum bactericidal activities of vancomycin and teicoplanin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

In vivo pharmacodynamics of a new oxazolidinone (linezolid)

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

The importance of bactericidal drugs: future directions in infectious disease.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

FDA evaluation of antimicrobials: subgroup analysis.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.4.539

21 January 2018

Identifiers

10.1592/PHCO.26.4.539

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36428418&oldid=2004849897"